2.1 Pharmacology, Mechanisms & Drug Classes
Key Takeaways
- A full agonist produces maximal receptor response; a partial agonist (e.g., buprenorphine) has lower intrinsic activity and can blunt the effect of a full agonist.
- Competitive antagonists shift the agonist dose-response curve right (surmountable); noncompetitive antagonists lower the maximal effect (insurmountable).
- Pharmacokinetic interactions change drug concentration (CYP450 induction/inhibition); pharmacodynamic interactions change drug effect at the same concentration.
- Strong CYP3A4 inhibitors (clarithromycin, ketoconazole, ritonavir, grapefruit juice) raise levels of substrates such as simvastatin, increasing toxicity risk.
- Most adverse effects are mechanism-based extensions of pharmacology; beta-blocker bronchospasm and NSAID renal injury are predictable type A reactions.
Why This Matters
Pharmacology is the backbone of the North American Pharmacist Licensure Examination (NAPLEX). Foundational Knowledge is 25% of the exam, and almost every clinical question in the larger 40% Person-Centered domain assumes you already know how a drug works. If you can reason from mechanism, you can predict efficacy, adverse effects, and interactions instead of memorizing isolated facts.
Receptor Pharmacology
Most drugs act by binding a receptor — a protein that transduces a chemical signal into a cellular response. Two properties define drug-receptor behavior:
- Affinity — how tightly a drug binds its receptor. High affinity means binding occurs at low concentration.
- Intrinsic activity (efficacy) — how strongly the bound drug activates the receptor once attached.
The potency of a drug (its EC50, the concentration producing 50% of maximal effect) reflects affinity. The efficacy (Emax, the maximal achievable effect) reflects intrinsic activity. A more potent drug is not necessarily more effective.
Agonists and Antagonists
| Ligand type | Intrinsic activity | Clinical example |
|---|---|---|
| Full agonist | Maximal (1.0) | Morphine at the mu-opioid receptor |
| Partial agonist | Submaximal (>0, <1) | Buprenorphine, aripiprazole |
| Antagonist | None (0) | Naloxone, propranolol |
| Inverse agonist | Negative (reduces basal activity) | Some antihistamines, beta-carbolines |
A partial agonist is clinically important because it can act like an antagonist in the presence of a full agonist: buprenorphine displaces morphine but produces less mu-opioid effect, which can precipitate withdrawal in an opioid-dependent patient.
Competitive vs. Noncompetitive Antagonism
- A competitive antagonist binds reversibly at the agonist site. It shifts the agonist dose-response curve to the right but Emax is unchanged — the block is surmountable with more agonist. Example: naloxone reversing opioid overdose.
- A noncompetitive (irreversible or allosteric) antagonist lowers Emax and cannot be overcome by adding agonist — the block is insurmountable. Example: phenoxybenzamine at alpha-adrenergic receptors.
High-Yield Drug Classes and Mechanisms
Know the canonical mechanism for each major class. A representative, non-exhaustive set:
- ACE inhibitors (lisinopril) — block conversion of angiotensin I to angiotensin II; reduce afterload; dry cough from bradykinin accumulation.
- Angiotensin receptor blockers (losartan) — block the AT1 receptor; no bradykinin-mediated cough.
- Beta-blockers (metoprolol) — block beta-1 receptors, lowering heart rate and contractility; nonselective agents (propranolol) also block beta-2, risking bronchospasm.
- Statins (atorvastatin) — inhibit HMG-CoA reductase, the rate-limiting step in cholesterol synthesis; upregulate LDL receptors.
- Proton pump inhibitors (omeprazole) — irreversibly inhibit the gastric H+/K+ ATPase.
- Selective serotonin reuptake inhibitors (sertraline) — block the serotonin transporter, increasing synaptic serotonin.
- Beta-lactams (amoxicillin) — inhibit penicillin-binding proteins, disrupting bacterial cell-wall synthesis.
- Direct oral anticoagulants — apixaban/rivaroxaban inhibit factor Xa; dabigatran directly inhibits thrombin (factor IIa).
Structure-Activity Relationship Basics
The structure-activity relationship (SAR) describes how a molecule's chemical structure determines its biological activity. NAPLEX expects practical, not synthetic-chemistry, reasoning:
- Small structural changes alter potency, selectivity, and pharmacokinetics. Adding a fluorine or methyl group can slow metabolism and extend half-life.
- Stereochemistry matters: enantiomers can differ in activity (e.g., S-warfarin is more potent and more affected by CYP2C9 than R-warfarin; esomeprazole is the S-enantiomer of omeprazole).
- Prodrugs require bioactivation — enalapril → enalaprilat, codeine → morphine (via CYP2D6), clopidogrel → active thiol (via CYP2C19). Poor metabolizers may underrespond to a prodrug.
- Lipophilicity governs central nervous system penetration: lipophilic beta-blockers (propranolol) cause more CNS effects than hydrophilic atenolol.
Drug Interactions: Pharmacokinetic vs. Pharmacodynamic
Pharmacokinetic (PK) interactions change the concentration of a drug by altering absorption, distribution, metabolism, or excretion.
- Enzyme inhibition acts fast and raises substrate levels. Strong cytochrome P450 (CYP) 3A4 inhibitors — clarithromycin, ketoconazole, ritonavir, grapefruit juice — increase simvastatin exposure and rhabdomyolysis risk.
- Enzyme induction is delayed (days to weeks) and lowers substrate levels. Rifampin, carbamazepine, phenytoin, and St. John's wort induce CYP3A4 and can cause oral-contraceptive or warfarin failure.
- Transporter and absorption interactions: polyvalent cations (calcium, iron, antacids) chelate fluoroquinolones and tetracyclines, reducing absorption.
Pharmacodynamic (PD) interactions change the effect at an unchanged concentration — additive, synergistic, or antagonistic. Examples: opioids plus benzodiazepines (additive respiratory depression); multiple serotonergic agents (serotonin syndrome); a nonselective beta-blocker blunting albuterol's bronchodilation.
Autonomic Pharmacology: A High-Yield Framework
The autonomic nervous system underlies a large share of foundational and clinical items, and reasoning from receptor location predicts most effects.
| Receptor | Main location | Activation effect |
|---|---|---|
| Alpha-1 | Vascular smooth muscle | Vasoconstriction, raised blood pressure, mydriasis |
| Beta-1 | Heart | Increased rate and contractility |
| Beta-2 | Bronchial/vascular smooth muscle | Bronchodilation, vasodilation |
| Muscarinic (M) | Glands, smooth muscle, heart (M2) | "Rest and digest": miosis, bradycardia, secretions, GI/bladder motility |
| Nicotinic | Ganglia, neuromuscular junction | Skeletal muscle contraction, ganglionic transmission |
From this map: a beta-2 agonist (albuterol) bronchodilates; an anticholinergic (oxybutynin, diphenhydramine) causes the classic toxidrome "dry as a bone, red as a beet, blind as a bat, mad as a hatter" (dry mouth, flushing, blurred vision, confusion, urinary retention). A cholinergic excess (organophosphate poisoning) produces the SLUDGE picture — salivation, lacrimation, urination, defecation, GI distress, emesis — reversed with atropine. Predicting these from receptor location is faster and more reliable than memorizing side-effect lists.
Adverse-Effect Mechanisms
Most adverse drug reactions are predictable from pharmacology.
- Type A (augmented) — dose-related extensions of the drug's known action: hypoglycemia from insulin, bleeding from anticoagulants, bradycardia from beta-blockers, acute kidney injury from nonsteroidal anti-inflammatory drugs (NSAIDs) reducing renal prostaglandins. These are common and usually manageable with dose adjustment.
- Type B (bizarre) — not predictable from pharmacology; immunologic or idiosyncratic: penicillin anaphylaxis, malignant hyperthermia, idiosyncratic hepatotoxicity.
Beyond Types A and B, the exam may reference Type C (chronic/cumulative, e.g., osteoporosis from long-term corticosteroids), Type D (delayed, e.g., teratogenesis or secondary malignancy), and Type E (end-of-treatment withdrawal, e.g., rebound hypertension after abrupt clonidine cessation). Recognizing the category points to the right management — dose-reduce a Type A, avoid re-exposure for a Type B, and taper to prevent a Type E.
On the Exam: When asked to predict an adverse effect, first identify the drug's mechanism, then extend it. A nonselective beta-blocker blocks beta-2 receptors → bronchoconstriction in asthma. An ACE inhibitor reduces aldosterone → hyperkalemia. This reasoning chain answers many NAPLEX items without rote memorization.
A patient on chronic morphine for cancer pain is given buprenorphine. Within 30 minutes the patient develops agitation, sweating, and abdominal cramping. Which property of buprenorphine best explains this reaction?
Phenoxybenzamine produces an alpha-adrenergic block that cannot be reversed by giving high doses of norepinephrine, and the maximal achievable response is reduced. This is best described as:
A patient stabilized on warfarin starts rifampin for tuberculosis. Two weeks later the INR is subtherapeutic despite the same warfarin dose. The most likely mechanism is:
Which adverse effect is best classified as a Type A (augmented), mechanism-based reaction?
A patient who took a large dose of diphenhydramine presents with dry mouth, flushed skin, blurred vision, urinary retention, and confusion. Which receptor mechanism explains this toxidrome?